Top Markets
Coin of the day
Gilead Sciences, Inc. Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD
Peringkat dalam Saham #100
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations... Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
Harga Saham
$150.78
Terakhir disinkronkan: 2026-09-18
Kapitalisasi Pasar
$187.20B
Perubahan (1 hari)
-0.08%
Perubahan (1 tahun)
32.15%
Negara
US
Perdagangan Gilead Sciences, Inc. (GILD)

Kategori

Rasio P/B untuk Gilead Sciences, Inc. (GILD)
Rasio P/B per September 2026 TTM: 15.39
Menurut laporan keuangan dan harga saham terbaru dari Gilead Sciences, Inc., rasio P/B saat ini (TTM) adalah 15.39. Pada akhir 2024, rasio P/B perusahaan adalah 5.96.
Riwayat rasio P/B untuk Gilead Sciences, Inc. dari 2000 hingga 2026
Rasio P/B pada akhir setiap tahun
Tahun Rasio P/B Mengubah
2026 (TTM) 15.39 -100.00%
2025 0.00 -100.00%
2024 5.96 34.58%
2023 4.43 -12.71%
2022 5.07 17.19%
2021 4.33 7.59%
2020 4.02 9.82%
2019 3.66 -3.49%
2018 3.80 -17.12%
2017 4.58 -9.78%
2016 5.08 -36.48%
2015 7.99 -14.05%
2014 9.30 -7.89%
2013 10.10 68.83%
2012 5.98 27.09%
2011 4.71 -11.06%
2010 5.29 -13.96%
2009 6.15 -44.20%
2008 11.02 -10.79%
2007 12.35 -24.75%
2006 16.42 108.13%
2005 7.89 -2.41%
2004 8.08 -30.89%
2003 11.69 0.49%
2002 11.64 -15.83%
2001 13.83 28.66%
2000 10.75 0.00%
Rasio P/B untuk perusahaan sejenis atau pesaing
Perusahaan Rasio P/B Perbedaan Rasio P/B Negara
29.9692 94.78%
US
7.6479 -50.29%
US
-78.0908 -607.54%
US
8.4776 -44.90%
CH
8.5385 -44.51%
US